Insider · CIK 0001588861
Sujal Shah
Files at TVRD (Tvardi Therapeutics, Inc.). First filing -, latest -.
Sujal Shah files SEC Form 4 as director at TVRD (Tvardi Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sujal Shah has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jun 11, 2026 |
| Apr 17, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Apr 21, 2025 |
| Apr 15, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,394 | - | - | 10,394 | Apr 17, 2025 |
| Apr 15, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +8,047 | - | - | 8,047 | Apr 17, 2025 |
Questions about Sujal Shah
Answered from the filings on this page, as of the latest one.
Is Sujal Shah buying or selling?
Sujal Shah has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sujal Shah's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sujal Shah has 0.
Where does Sujal Shah file Form 4?
Sujal Shah has filed Form 4 at TVRD (Tvardi Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.